Genomics

Together, We Beat Cancer

We perform DNA and RNA Next Generation-Sequencing (NGS) based genetic testing to generate high-quality molecular genetic data. This is achieved by analyzing Somatic and Germline variants, thereby empowering oncologists to make genomic data-driven personalized treatment decisions for their cancer patients. Clinically relevant genomic biomarkers are analyzed and prioritized based on the strength of the clinical evidence, which provides insights into relevant therapeutic options (targeted and Immunotherapy).

Our Liquid biopsy panel utilizes the ctDNA approach to provide comprehensive information on the biology of the tumor in terms of its current status and its response to therapy from peripheral blood.

Our interdisciplinary team of cancer researchers, bioinformaticians, and data scientists uses in-house developed custom algorithms that include complex mathematical and statistical models for in-depth curation and correlation of published scientific findings and clinical research to provide the most updated and best treatment recommendations.

Somatic Tests

Somatic genetic/genomic tests in cancer are typically performed on tumor tissue (FFPE block/Fresh tissue) to identify somatic mutations, which might help identify the clinically actionable genomic alterations for cancer patients. Our TARGT (Tumor-Associated Drug Response by Genomic Testing) portfolio of genetic/genomic tests is validated to identify somatic mutations in the tumor tissue with high sensitivity and specificity to detect even low-frequency genomic alterations/aberrations/mutations that drive cancer.

All the tests under the TARGT portfolio identify genetic variants associated with approved treatment and clinical trials. TARGT tests report actionable and targetable somatic mutations, which include SNVs, Indels, CNAs, and Genomic Signatures like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).

Click on the below icons to know more about our Somatic Tests


Hereditary Cancer Test

Genetic variations/mutations/aberrations in the genes you are born with can increase your cancer risk. Our NGS (Next-Generation Sequencing) based Hereditary Cancer genetic test - Germline+ analyses 213 genes associated with cancer risk DDR (DNA Damage Repair) and HRR (Homologous Recombination Repair) pathway. The panel includes genes associated with familial and hereditary cancers (Breast, Ovarian, Prostate, Pancreatic, etc).

As per ACMG guidelines, the detected variants are classified as: pathogenic, likely pathogenic, VUS, likely benign, and benign. This may attribute to a high, moderate, or low risk of getting cancer.

Some of the Germline variants like in the BRCA gene not just help in identifying cancer risk but also help in making PARP (Poly-ADP-Ribose Polymerase) inhibitor targeted therapy treatment decisions.

Click on the below icon to know more about our Hereditary Cancer Test


Liquid Biopsy Assay

Liquid biopsy is a minimally invasive blood-based assay that has a role in diagnostic, and prognostic as well as therapeutic treatment-related decisions for cancer patients.

The assay isolates and detects tumor genomes and associated genomic alterations such as SNVs/InDels, CNAs, and Gene Fusions from peripheral blood.

Liquid biopsies have been recognized as a valuable diagnostic and monitoring tool. With FDA approving the use of liquid biopsies for Non-Small Cell Lung Cancer and other solid tumors, oncologists around the globe are utilizing this technique for various cancer patients. 

The technique of liquid biopsy involves drawing blood from the cancer patient and analyzing the presence of tumor or tumor content in the bloodstream. When compared to tissue biopsies, liquid biopsies are quicker, easier, less painful, and are considered to be minimally invasive as it requires only drawing of blood from the patient. The technique involves extracting tumor DNA from blood followed by NGS analysis for precise cancer management.

Click on the below icon to know more about our Liquid Biopsy Assay


loader